In prostate cancer, the TNM system fails to include serum PSA levels, the principal tool for screening and early detection as well as the best predictor of pathological stage and prognosis.

The choice of treatment options for prostate cancer patients who have undergone radical prostatectomy depends on their risk profile, which is determined by the tumor node metastasis (TNM ...

They often use the American Joint Committee on Cancer (AJCC) TNM system, in which the following three factors determine ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Wolfgang P.